Acadia Shares Climb After EMA Panel Recommends DAYBU for Rett Syndrome Symptoms
Acadia Pharmaceuticals' stock rose after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending DAYBU (trofinetide) for treating neurobehavioral symptoms of Rett syndrome in patients aged five and older. The recommendation, based principally on results from the Phase 3 LAVENDER trial, w…